ArticleCurrent urology2026
Role of miR-34a/KLF4 axis in podocyte injury and obesity-related glomerulopathy with preliminary observations in clear cell renal cell carcinoma.
Article in Current urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to investigate the role of miR34a in obesity-related glomerular disease using an experimental mouse model induced by a high-fat diet and a podocyte injury model induced by palmitic acid. Materials and methods: An obese mouse model was established by high-fat feeding, followed by analysis of renal pathology, immunohistochemistry, and detection of miR34a and Krüppel-like factor 4 (KLF4) levels. In vitro experiments involved treating podocytes with varying concentrations of palmitic acid, performing Oil Red O staining, assessing related indicators and apoptosis, and transfection with miR34a mimics or inhibitors to evaluate their effects. The target relationship was validated using a luciferase assay. The differential expression of miR34a in clear cell renal cell carcinoma (ccRCC) and adjacent normal tissue was detected using RT-qPCR. Results: A high-fat diet was successfully used to establish an obese mouse model, which led to a significantly increased glomerular volume. Renal tissues exhibited decreased KLF4 and nephrin levels and increased Bak and cleaved CASP9 levels. miR34a was negatively correlated with KLF4 and positively correlated with Bak, suggesting the potential induction of apoptosis through KLF4. Cell experiments demonstrated that palmitic acid upregulated miR34a, downregulated KLF4, and induced podocyte apoptosis. Furthermore, miR34a mimics exacerbated apoptosis, whereas miR34a inhibitors alleviated apoptosis. A dual-luciferase assay confirmed that miR34a targeted and inhibited KLF4 expression. miR-34a expression was upregulated in ccRCC compared with adjacent normal renal tissues, and this tendency was more prominent in obese patients. Conclusions: Elevated miR34a levels may contribute to podocyte injury by inhibiting KLF4, thereby promoting the progression of obesity-related glomerulopathy. miR34a may also be related to the pathogenesis of ccRCC, especially in obese patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.